Your search for "livestock" return 46 results.
Ceva and Sogeval in exclusive negotiations to create a global leader in animal health >
Ceva and Sogeval (a subsidiary of Sofiprotéol), based in Laval announce the opening of exclusive negotiations to create a future alliance.
Ceva’s growth continues despite difficult market conditions >
Libourne, France, 22 July, 2013: Consolidated sales of the Ceva Group reached €310m in the first 6 months of 2013, up by 2%, 4.2% on the previous year at a constant perimeter and exchange rates. C...
Ceva signs a Joint-venture agreement in China to help control zoonoses >
Joint-venture with Jinyu Baoling will produce brucellosis vaccines in Inner Mongolia
Signature of a scientific collaboration protocol about avian influenza with South China Agricultural University >
Paris, May 29th 2013 1- Ceva, a socially responsible company committed to the well-being of the planet Ceva Santé Animale is a multi-national French based animal health company that counts over 3000 e...
AXA Private Equity provides additional financing to support the development of Ceva >
AXA Private Equity, the leading European diversified private equity firm, announces today that it is providing €100 million of additional financing to support the development of Ceva.
Mid-year results : Innovation drives Ceva’s growth >
Double-digit growth confirms long term upward trend
Ceva Workshop at the European Buiatrics Forum >
Challenges in cattle reproduction was the focus of a workshop organized by Ceva Santé Animale as part of the European Buiatrics Forum which took place in November in the French city of Marseilles.
Joint Venture agreement between Ceva and Huadu signed in Beijing >
“Ceva Huadu” to become Innovation & R&D platform for biologicals
Ceva opens new production facility in Lenexa, Kansas >
May 3, 2011, Lenexa, Kan. –– Ceva Animal Health is pleased to announce the May 3, 2011 opening of a new poultry vaccine production facility at its Biomune Campus in Lenexa, Kansas.
Ceva launches latest of its Vector Vaccines at VIV Asia 2011 >
VECTORMUNE HVT- NDV® generates strong interest at symposium organised to present new strategies to combat Newcastle Disease.